Background: Immunization against SARS-CoV-2, the causative agent of coronavirus disease-19 (COVID-19) occurs via natural infection or vaccination. However, it is currently unknown how long infection- or vaccination-induced immunological memory will last. Methods: We performed a longitudinal evaluation of immunological memory to SARS-CoV-2 up to one year post infection and following mRNA vaccination in naïve and COVID-19 recovered individuals. Results: We found that memory cells are still detectable 8 months after vaccination, while antibody levels decline significantly especially in naïve subjects. We also found that a booster injection is efficacious in reactivating immunological memory to spike protein in naïve subjects, while it results ineffective in previously SARS-CoV-2 infected individuals. Finally, we observed a similar kinetics of decay of humoral and cellular immunity to SARS-CoV-2 up to one year following natural infection in a cohort of unvaccinated individuals. Conclusion: Short-term persistence of humoral immunity, together with the reduced neutralization capacity versus the currently prevailing SARS-CoV-2 variants, may account for reinfections and breakthrough infections. Long-lived memory B and CD4+ T cells may protect from severe disease development. A booster dose restores optimal anti-spike immunity in naïve subjects, while the need for vaccinated COVID-19 recovered subjects has yet to be defined. Trial registration: naFUNDING. This study was supported by funds to the Department of Experimental and Clinical Medicine, University of Florence (Project Excellence Departments 2018-2022), by the University of Florence, project RICTD2122, by the Italian Ministry of Health (COVID-2020-12371849) and by Tuscany Region (TagSARS CoV 2).
SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes: implications for booster strategies / Mazzoni, Alessio; Vanni, Anna; Spinicci, Michele; Lamacchia, Giulia; Kiros, Seble Tekle; Rocca, Arianna; Capone, Manuela; Lauria, Nicoletta; Salvati, Lorenzo; Carnasciali, Alberto; Mantengoli, Elisabetta; Farahvachi, Parham; Zammarchi, Lorenzo; Lagi, Filippo; Colao, Maria Grazia; Liotta, Francesco; Cosmi, Lorenzo; Maggi, Laura; Bartoloni, Alessandro; Rossolini, Gian Maria; Annunziato, Francesco. - In: THE JOURNAL OF CLINICAL INVESTIGATION. - ISSN 1558-8238. - ELETTRONICO. - (2022), pp. 0-0. [10.1172/JCI157990]
SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes: implications for booster strategies
Mazzoni, Alessio;Vanni, Anna;Spinicci, Michele;Lamacchia, Giulia;Kiros, Seble Tekle;Rocca, Arianna;Capone, Manuela;Lauria, Nicoletta;Salvati, Lorenzo;Carnasciali, Alberto;Mantengoli, Elisabetta;Farahvachi, Parham;Zammarchi, Lorenzo;Lagi, Filippo;Liotta, Francesco;Cosmi, Lorenzo;Maggi, Laura;Bartoloni, Alessandro;Rossolini, Gian Maria;Annunziato, Francesco
2022
Abstract
Background: Immunization against SARS-CoV-2, the causative agent of coronavirus disease-19 (COVID-19) occurs via natural infection or vaccination. However, it is currently unknown how long infection- or vaccination-induced immunological memory will last. Methods: We performed a longitudinal evaluation of immunological memory to SARS-CoV-2 up to one year post infection and following mRNA vaccination in naïve and COVID-19 recovered individuals. Results: We found that memory cells are still detectable 8 months after vaccination, while antibody levels decline significantly especially in naïve subjects. We also found that a booster injection is efficacious in reactivating immunological memory to spike protein in naïve subjects, while it results ineffective in previously SARS-CoV-2 infected individuals. Finally, we observed a similar kinetics of decay of humoral and cellular immunity to SARS-CoV-2 up to one year following natural infection in a cohort of unvaccinated individuals. Conclusion: Short-term persistence of humoral immunity, together with the reduced neutralization capacity versus the currently prevailing SARS-CoV-2 variants, may account for reinfections and breakthrough infections. Long-lived memory B and CD4+ T cells may protect from severe disease development. A booster dose restores optimal anti-spike immunity in naïve subjects, while the need for vaccinated COVID-19 recovered subjects has yet to be defined. Trial registration: naFUNDING. This study was supported by funds to the Department of Experimental and Clinical Medicine, University of Florence (Project Excellence Departments 2018-2022), by the University of Florence, project RICTD2122, by the Italian Ministry of Health (COVID-2020-12371849) and by Tuscany Region (TagSARS CoV 2).File | Dimensione | Formato | |
---|---|---|---|
157990.2-20220307123914-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
1.97 MB
Formato
Adobe PDF
|
1.97 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.